Opinion|Videos|July 16, 2026
Clinical Evidence: What the Trial Data Tell Pharmacists
Menin inhibitors show promising AML responses—revumenib enables remissions and transplant bridging, while new combinations target KMT2A and NPM1.
Episodes in this series
In this episode, Ali breaks down the pivotal trial data for revumenib and ziftomenib, comparing response rates, transplant outcomes, and patient populations studied. He reveals which efficacy numbers pharmacists should know before their first order review and explains why transplant rate is as clinically meaningful as overall response rate when evaluating therapy success.
Latest CME
Trending on Pharmacy Times
1
Cyclosporiasis Cases Reach 5100: Investigators Zero In On Lettuce, Possible Taco Bell Link
2
Patient-Reported Outcomes, Machine Learning May Predict Breast Cancer Recurrence Earlier
3
Subcutaneous Olanzapine in Schizophrenia: Expanding the Utility of a Proven Therapy
4
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
5